drugset / Trial / NCT03022565
Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
Phase 0
Withdrawn
University of Miami
University of Miami Sylvester Comprehensive Cancer Center · collab
NaSingle-groupOpen-labelTreatment
Summary
This proof-of-concept study will evaluate the ability of vorinostat to induce the transformation of Class 2 uveal melanoma cells into a cell phenotype that resembles normal melanocytes.
Timeline
- Start
- 2020-01
- Primary completion
- 2020-01-29
- Completion
- 2020-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | 400 mg | Oral |